Human Genome Sciences, Inc (HGSI)

[surf1944]

6:25AM Human Genome trades above $14 pre-market after co announced earlier that it has received an unsolicited proposal from GlaxoSmithKline (GSK) to acquire HGSI for $13.00/share; Board believes $13 offer does not reflect value inherent in Company (HGSI) 7.17 : The HGS Board of Directors, in consultation with independent financial and legal advisors, has carefully reviewed and considered the GSK offer and has determined that the offer does not reflect the value inherent in HGS. HGS also announced today that its Board of Directors has authorized the exploration of strategic alternatives in the best interests of shareholders, including, but not limited to, a potential sale of the Company. HGS has retained Goldman, Sachs & Co. and Credit Suisse Securities to assist in this process. GSK has been invited to participate in this process and HGS has requested additional information regarding investigational products in GSK's clinical pipeline to which HGS has substantial financial rights, including darapladib, currently in Phase 3 development for the treatment of cardiovascular disease, and albiglutide, currently in Phase 3 development for the treatment of type 2 diabetes.